Welcome to our dedicated page for AirSculpt Technologies news (Ticker: AIRS), a resource for investors and traders seeking the latest updates and insights on AirSculpt Technologies stock.
AirSculpt Technologies, Inc. provides premium body contouring procedures through AirSculpt offices. Its AirSculpt method is a minimally invasive treatment for fat removal, skin tightening, targeted body sculpting, and fat transfer procedures that use a patient’s own fat cells.
Company news centers on operating results, same-center and same-store sales trends, case volume, revenue, adjusted EBITDA, guidance, marketing initiatives, new procedure categories, balance sheet activity, and governance changes. Updates also address the company’s positioning within aesthetics demand tied to GLP-1 use and its direct medical procedure services model.
AirSculpt Technologies announces a leadership change with Todd Magazine appointed as the new CEO, effective at the end of January 2023. Dr. Aaron Rollins, the company's founder, moves to the role of Executive Chairman, focusing on strategic guidance. Magazine, with over 30 years of experience in retail and brand building, aims to leverage AirSculpt's proprietary technology to accelerate growth. The company maintains its full-year 2022 revenue guidance of $168-$170 million, indicating stable financial expectations moving forward.
AirSculpt® Technologies (NASDAQ: AIRS) is set to showcase the results of body contouring procedures performed on former Real Housewives stars Vicki Gunvalson and LeeAnne Locken via Instagram Live on December 15. The event will reveal their experiences documented through AirSculpt TV. Participants shared positive feedback about the quick recovery and transformative results from their AirSculpt treatments. With over 30,000 procedures performed, the company focuses on providing minimally invasive body contouring solutions through its Elite Body Sculpture brand.
AirSculpt Technologies (NASDAQ: AIRS) announces the opening of its first international Elite Body Sculpture location in London, set for the first half of 2023. This expansion aims to broaden its reach and enhance its premium body contouring services. The company plans to open a total of five new locations in 2023. Dr. Aaron Rollins, CEO, expressed enthusiasm for the London location, highlighting a luxury experience for clients, and welcomed Rana Das-Gupta as the new Medical Director, emphasizing his expertise in body fat reduction.
AirSculpt Technologies (NASDAQ: AIRS) announces the opening of its first international Elite Body Sculpture center in Toronto, Canada, marking a significant milestone in its global expansion. This new location offers AirSculpt's premium, minimally invasive body contouring procedures aimed at providing comfort and precision. The founder, Dr. Aaron Rollins, emphasized the rising demand for the proprietary AirSculpt method, promising Canadians enhanced body transformation experiences. For more information about the Toronto site and services, visit www.airsculpt.ca.
AirSculpt Technologies (NASDAQ:AIRS) reported a 12.2% revenue increase to $38.9 million for Q3 2022, driven by new center openings. However, a net loss of $7.4 million was recorded, impacted by increased equity compensation and public company expenses. Year-to-date revenue rose 33.8% to $128.1 million, with a case volume growth of 19.1%. Adjusted EBITDA decreased to $9.2 million, affected by rising costs. The Company lowered its 2022 revenue outlook to $168-170 million and adjusted EBITDA forecast to $45-47 million, while planning four new center openings.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) has announced a new credit agreement with lenders, securing $85 million in term loans and a $5 million revolving loan facility. This funding will pay off an existing $83.6 million credit facility due October 28, 2023. The new agreement, maturing on November 7, 2027, is expected to save the company approximately $2 million annually in cash interest, with no prepayment penalties. CFO Dennis Dean expressed satisfaction with the refinancing, noting it provides flexibility to pursue strategic growth plans.
AirSculpt Technologies, Inc. (NASDAQ: AIRS) has announced the opening of its new centers in Philadelphia and Boston, bringing the total to 21 locations across the U.S. The company specializes in premium body contouring procedures utilizing its proprietary AirSculpt technology, known for its minimally invasive approach that facilitates faster healing and more precise results. Over 30,000 procedures have been conducted nationally, indicating a robust demand for their services. The Boston center opened in July, while the Philadelphia center is centrally located near King of Prussia Mall.
AirSculpt Technologies (NASDAQ: AIRS) has announced that it will release its third quarter results on November 10, 2022, after market close. Following this, a conference call will be held on November 11, 2022, at 8:30 AM ET for investors and the public to discuss the results. Access to the call is available via phone or through a webcast on the company's investor relations website. AirSculpt is known for its proprietary AirSculpt® method, which offers a minimally invasive body contouring procedure aiming to deliver significant results for patients.
AirSculpt Technologies (NASDAQ: AIRS) announced management's participation at the Piper Sandler Growth Frontiers Conference in Nashville, TN on September 13, 2022. The event will include 1x1 investor meetings and a fireside chat at 5:00 PM ET. A live webcast and replay will be accessible on AirSculpt's investor relations site.
AirSculpt specializes in premium body contouring procedures, using its proprietary AirSculpt® method for minimally invasive fat removal, aiming to deliver exceptional results for patients.
AirSculpt Technologies (NASDAQ: AIRS) has introduced AirSculpt Smooth, a new cellulite removal procedure that is FDA-cleared and minimally invasive. This one-time procedure offers complete removal of stubborn cellulite dimples and is designed to be performed alongside AirSculpt's fat removal method. Clients can expect to resume normal activities within 24-48 hours. The procedure utilizes the Aveli device from Revelle Aesthetics and aims to provide lasting results that improve over three months, enhancing the body contouring experience.